Get the Stockscreener App
7.09
2.61%
-0.19
After Hours:
7.04
-0.05
-0.71%
Diamedica Therapeutics Inc stock is traded at $7.09, with a volume of 418.70K.
It is down -2.61% in the last 24 hours and up +35.82% over the past month.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
See More
Previous Close:
$7.28
Open:
$7.29
24h Volume:
418.70K
Relative Volume:
1.06
Market Cap:
$366.47M
Revenue:
-
Net Income/Loss:
$-19.90M
P/E Ratio:
-13.38
EPS:
-0.53
Net Cash Flow:
$-19.80M
1W Performance:
+15.47%
1M Performance:
+35.82%
6M Performance:
+22.24%
1Y Performance:
+65.27%
1-Day Range:
$7.05
$7.35
1-Week Range:
$6.57
$7.4899
52-Week Range:
$3.19
$7.4899
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Name
Diamedica Therapeutics Inc
Sector
Industry
Phone
(763) 496-5454
Address
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
7.09 | 368.54M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Jun-22-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-09-21 | Initiated | Oppenheimer | Outperform |
| Feb-17-21 | Initiated | ROTH Capital | Buy |
| Oct-30-20 | Initiated | Guggenheim | Buy |
| Jul-08-20 | Initiated | Maxim Group | Buy |
| Apr-30-19 | Initiated | Dougherty & Company | Buy |
| Mar-05-19 | Initiated | Lake Street | Buy |
View All
Diamedica Therapeutics Inc Stock (DMAC) Latest News
Heatmap analysis for DiaMedica Therapeutics Inc. and competitorsVolume Spike & Expert Curated Trade Setups - Newser
Candlestick signals on DiaMedica Therapeutics Inc. stock todayTrade Exit Summary & Low Risk Profit Maximizing Plans - Newser
Visualizing DiaMedica Therapeutics Inc. stock with heatmapsJuly 2025 Rallies & Low Drawdown Trading Strategies - Newser
Chart based analysis of DiaMedica Therapeutics Inc. trendsMarket Movement Recap & Reliable Breakout Forecasts - Newser
Trend analysis for DiaMedica Therapeutics Inc. this weekQuarterly Profit Summary & Weekly High Return Forecasts - Newser
Volatility clustering patterns for DiaMedica Therapeutics Inc.Global Markets & Stepwise Trade Execution Plans - Newser
Historical volatility pattern of DiaMedica Therapeutics Inc. visualized2025 Institutional Moves & Weekly Watchlist for Hot Stocks - Newser
Automated trading signals detected on DiaMedica Therapeutics Inc.Weekly Earnings Recap & Verified Short-Term Plans - Newser
Key metrics from DiaMedica Therapeutics Inc.’s quarterly dataDollar Strength & Growth Focused Investment Plans - Newser
How to build a custom watchlist for DiaMedica Therapeutics Inc.Market Risk Report & Community Trade Idea Sharing Platform - Newser
Will DiaMedica Therapeutics Inc. price bounce be sustainable2025 Valuation Update & High Accuracy Trade Alerts - Newser
Combining price and volume data for DiaMedica Therapeutics Inc2025 Valuation Update & AI Based Buy and Sell Signals - Newser
Combining price and volume data for DiaMedica Therapeutics Inc.Quarterly Performance Summary & Fast Moving Market Watchlists - Newser
Statistical indicators supporting DiaMedica Therapeutics Inc.’s strengthAnalyst Upgrade & Community Verified Watchlist Alerts - Newser
Is DiaMedica Therapeutics Inc. stock entering bullish territoryJuly 2025 Trade Ideas & Smart Swing Trading Techniques - Newser
Pattern recognition hints at DiaMedica Therapeutics Inc. upsideQuarterly Earnings Report & Safe Entry Point Alerts - Newser
DiaMedica Therapeutics Inc.’s volatility index tracking explainedM&A Rumor & High Win Rate Trade Tips - Newser
How to recover losses in DiaMedica Therapeutics Inc. stockQuarterly Earnings Summary & Stepwise Trade Execution Plans - Newser
Stocks In Play: Empire Company Limited - Barchart.com
Can DiaMedica Therapeutics Inc. hit a new high this monthJuly 2025 PostEarnings & Safe Entry Trade Reports - Newser
Using AI based signals to follow DiaMedica Therapeutics Inc.2025 Big Picture & Advanced Swing Trade Entry Plans - Newser
Is DiaMedica Therapeutics Inc. a candidate for recovery play2025 Risk Factors & Weekly Watchlist for Consistent Profits - Newser
DiaMedica Therapeutics (NASDAQ:DMAC) Upgraded to Hold at Wall Street Zen - MarketBeat
How sentiment analysis helps forecast DiaMedica Therapeutics Inc.Market Trend Review & Accurate Trade Setup Notifications - Newser
DiaMedica Therapeutics Inc. stock outlook for YEARMarket Movement Recap & Expert Verified Movement Alerts - Newser
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating - 富途牛牛
This Hidden Gem Biotech is the Only Small-Cap Among Billionaire Investor Leon Cooperman's Top Market-Beating Picks - Barchart.com
Bullish DiaMedica Therapeutics Insiders Rewarded As Their Investment Rises To US$79.8m - 富途牛牛
After Golden Cross, DiaMedica Therapeutics, Inc. (DMAC)'s Technical Outlook is Bright - Yahoo Finance
MDA SPACE RECOGNIZED AS A TSX30 COMPANY - Barchart.com
Diamedica Therapeutics Inc Stock (DMAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):